India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US

SelfRugger · 2026-02-11T10:38:18+00:00

Lupin Pharmaceuticals has resolved a patent dispute with Astellas Pharma regarding Mirabegron, permitting continued sales in the U.S. The agreement involves a $90 million payment, with $75 million upfront and additional licensing fees.

SelfRugger

2026-02-11 10:38:18

Abstract generation in progress

India’s Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US

1 / 2

FILE PHOTO: The logo of Lupin, India’s No. 2 drugmaker, is seen on the facade of its pharmaceutical plant in Verna

FILE PHOTO: The logo of Lupin, India’s No. 2 drugmaker, is seen on the facade of its pharmaceutical plant in Verna, in the western state of Goa, India, June 9, 2017. Picture taken June 9, 2017. REUTERS/Danish Siddiqui/File Photo

        Full caption

Reuters

Tue, February 10, 2026 at 12:18 PM GMT+9 1 min read

In this article:

ALPMF

+7.72%

Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it has settled a patent ‌infringement dispute with Japan’s Astellas Pharma ‌over the bladder disorder drug Mirabegron, allowing it to continue selling the product in the ⁠United States.

Under ‌the agreement, Lupin and its U.S. unit will ‍pay Astellas $90 million, including a $75 million upfront payment and per-unit licensing fees on Mirabegron sales through ‌September 2027, the company said in an exchange filing.

The settlement resolves Lupin’s pending litigation with Astellas and enables the company ⁠to continue marketing Mirabegron in the United States.

Lupin had previously disclosed the patent dispute with ‍the Japanese ⁠drugmaker last April over its generic version of Myrbetriq, ⁠Astellas’ overactive bladder drug.

(Reporting by Surbhi ‌Misra in Bengaluru; Editing ‌by Sherry Jacob-Phillips)

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.